# Jie Wang

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jie-wang-2/

## Facts

| Field | Value |
| --- | --- |
| Citations | 18,661 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 58 |
| i10-index | 239 |
| Last Known Institution | Chinese Academy of Medical Sciences & Peking Union Medical College |
| OpenAlex ID | https://openalex.org/A5100440100 |
| ORCID iD | https://orcid.org/0000-0002-5602-0487 |
| Works | 630 |

## Researcher papers

- [Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study](https://scholariq.org/papers/erlotinib-versus-chemotherapy-as-first-line-treatment-for-patients-with-advanced/)
- [Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC](https://scholariq.org/papers/neoadjuvant-pd-1-inhibitor-sintilimab-in-nsclc/)
- [Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial](https://scholariq.org/papers/gefitinib-plus-chemotherapy-versus-placebo-plus-chemotherapy-in-egfr-mutation/)
- [Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/tislelizumab-plus-chemotherapy-vs-chemotherapy-alone-as-first-line-treatment-for/)
- [Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial](https://scholariq.org/papers/adjuvant-osimertinib-for-resected-egfr-mutated-stage-ib-iiia-non-small-cell-lung/)
- [Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-a-predominantly-chinese-patient-population-with/)
- [Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial](https://scholariq.org/papers/intercalated-combination-of-chemotherapy-and-erlotinib-for-patients-with/)
- [Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial](https://scholariq.org/papers/tislelizumab-plus-chemotherapy-as-first-line-treatment-for-locally-advanced-or/)
- [Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non–Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy](https://scholariq.org/papers/effect-of-postoperative-radiotherapy-for-patients-with-piiia-n2-non-small-cell/)
- [Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)](https://scholariq.org/papers/toripalimab-plus-chemotherapy-for-patients-with-treatment-naive-advanced-non/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Chinese Academy of Medical Sciences & Peking Union Medical College](https://scholariq.org/institutions/chinese-academy-of-medical-sciences-and-peking-union-medical-college/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.